128 results on '"Leuridan, E."'
Search Results
2. Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium
- Author
-
Leuridan, E., Maertens, K., Wautier, M., Hutse, V., and Theeten, H.
- Published
- 2015
- Full Text
- View/download PDF
3. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study
- Author
-
Leuridan, E, Hens, N, Hutse, V, Leven, M, Aerts, M, and Van Damme, P
- Published
- 2010
4. Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox
- Author
-
Ogunjimi, B., Van den Bergh, J., Meysman, P., Heynderickx, S., Bergs, K., Jansens, H., Leuridan, E., Vorsters, A., Goossens, H., Laukens, K., Cools, N., Van Tendeloo, Viggo, Hens, N., Van Damme, P., Smits, Evelien, and Beutels, Ph.
- Published
- 2017
- Full Text
- View/download PDF
5. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial
- Author
-
Wanlapakorn, N., Maertens, K., Peunpa, J., TRAN, Mai Phuong Thao, HENS, Niel, Van Damme, P., Thiriard, A., Raze, D., Locht, C., Poovorawan, Y., Leuridan, E., HENS, Niel, Poovorawan, Y., Thiriard, A., Leuridan, E., Wanlapakorn, N., Peunpa, J., TRAN, Mai Phuong Thao, Van Damme, P., Maertens, K., Raze, D., and Locht, C.
- Subjects
pertussis ,pregnancy ,maternal immunization ,functionality ,humoral immune response - Abstract
Background The blunting effect of maternal pertussis immunization during pregnancy on infant antibody responses induced by whole cell pertussis (wP) vaccination is not well-defined. Methods This randomized controlled trial (NCT02408926) followed term infants born to mothers vaccinated with tetanus-diphtheria-acellular pertussis (Tdap)-vaccine during pregnancy in Thailand. Infants received either acellular pertussis (aP)- or wP-containing vaccine at 2, 4, 6 and 18 months of age. A comparison group comprised wP-vaccinated children born to mothers not vaccinated during pregnancy. Antibodies against pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin (PRN) were evaluated using commercial enzyme-linked immunosorbent assays (ELISA). Functionality of antibodies against B. pertussis was measured using B. pertussis growth inhibition assay (BGIA). Results After maternal Tdap vaccination, 158 infants vaccinated with aP-containing vaccines possessed higher antibody levels (p < 0.001) against all tested B. pertussis antigens post-priming compared to 157 infants receiving wP-containing vaccines. At one-month post-booster, only anti-FHA and anti-PRN antibodies were still significantly higher (p < 0.001) in the aP group. Significantly higher anti-PT and anti-FHA (p < 0.001), but not anti-PRN IgG, were observed among 69 wP-vaccinated infants born to control mothers compared to wP-vaccinated infants of Tdap-vaccinated mothers after primary and booster vaccination. The antibody functionality was higher in all wP vaccinated infants at all times. Conclusions Maternal Tdap vaccination inhibited more pertussis-specific responses in wP vaccinated infants compared to aP vaccinated infants, and the control group of unvaccinated women had highest pertussis-specific responses, persisting until after the booster dose. Antibody functionality was better in the wP groups. Thrasher Research Fund Award (EWAT 12348) Thailand Research Fund (TRF) (IRG5780015) NSTDA Center of Excellence in Clinical Virology (GCE 58-014-30-004) National Vaccine Institute Department of Pediatrics, Faculty of Medicine, Chulalongkorn University Region Auvergne-Rhone-Alpes Region Bourgogne-Franche-Comte Region Hauts-de-France Region Nouvelle-Aquitaine Institut National de la Sante et de la Recherche Medicale (Inserm) FWO (FWO 12R5719N) European Research Council under the European Union's Horizon 2020 research and innovation program (682540-TransMID) Ratchadaphiseksomphot Endowment Fund
- Published
- 2020
6. The Effect of Tetanus-Diphtheria-Acellular-Pertussis Immunization During Pregnancy on Infant Antibody Responses: Individual-Participant Data Meta-Analysis
- Author
-
Abu-Raya, B, Maertens, K, Munoz, FM, Zimmermann, P, Curtis, N, Halperin, SA, Rots, N, Barug, D, Holder, B, Kampmann, B, Leuridan, E, Sadarangani, M, Abu-Raya, B, Maertens, K, Munoz, FM, Zimmermann, P, Curtis, N, Halperin, SA, Rots, N, Barug, D, Holder, B, Kampmann, B, Leuridan, E, and Sadarangani, M
- Abstract
BACKGROUND: Immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in pregnancy is increasingly recommended. We determined the effect of Tdap immunization in pregnancy on infants' vaccine responses. METHODS: Individual-participant data meta-analysis of ten studies (n=1884) investigating infants' antibody response to routine immunizations following Tdap immunization in pregnancy was performed. Geometric mean ratios (GMRs) of antigen-specific immunoglobulin G (IgG) levels were calculated using mixed-effects models. Seroprotection rates were compared using chi-squared tests. RESULTS: Infants of Tdap-immunized women had significantly lower IgG against pertussis toxin (GMR 0.65; 95%CI 0.57-0.74), filamentous haemagglutinin (FHA) (0.68; 0.53-0.87), pertactin (0.65; 0.58-0.72) and fimbria 2/3 (FIM2/3) (0.41; 0.32-0.52) after primary immunization, compared with infants of unimmunized women. These lower levels persisted after booster immunization for FHA (0.72; 0.61-0.84) and FIM2/3 (0.53; 0.29-0.96). After primary immunization, infants of Tdap-immunized women had lower seroprotection rates against diphtheria (90% [843/973] vs 98% [566/579]; p<0.001) and invasive pneumococcal disease (IPD) caused by 5 Streptococcus pneumoniae (SPN) serotypes (SPN5, SPN6B, SPN9V, SPN19A, SPN23F), and higher seroprotection rates against Haemophilus influenzae type b (short-term and long-term seroprotection rates, 86%[471/547] vs 76%[188/247] and 62%[337/547] vs 49%(121/247), respectively, all p=0.001). After booster immunization, seroprotection rates against diphtheria and tetanus were 99% (286/288) and (618/619) in infants of Tdap-immunized women, respectively. CONCLUSIONS: Infants of Tdap-immunized women in pregnancy had lower IgG levels against pertussis, diphtheria and some SPN serotypes after their immunization compared with infants of unimmunized women. Enhanced surveillance of pertussis, diphtheria and IPD in infants is needed to determine the clinical significance of t
- Published
- 2021
7. Maternal mumps antibodies in a cohort of children up to the age of 1 year
- Author
-
Leuridan, E., Goeyvaerts, N., Hens, N., Hutse, V., and Van Damme, P.
- Published
- 2012
- Full Text
- View/download PDF
8. Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement
- Author
-
Abu-Raya, B. Maertens, K. Edwards, K.M. Omer, S.B. Englund, J.A. Flanagan, K.L. Snape, M.D. Amirthalingam, G. Leuridan, E. Damme, P.V. Papaevangelou, V. Launay, O. Dagan, R. Campins, M. Cavaliere, A.F. Frusca, T. Guidi, S. O'Ryan, M. Heininger, U. Tan, T. Alsuwaidi, A.R. Safadi, M.A. Vilca, L.M. Wanlapakorn, N. Madhi, S.A. Giles, M.L. Prymula, R. Ladhani, S. Martinón-Torres, F. Tan, L. Michelin, L. Scambia, G. Principi, N. Esposito, S. World Association of Infectious Diseases Immunological Disorders (WAidid) the Vaccine Study Group of the European Society of Clinical Microbiology Infectious Diseases (EVASG)
- Abstract
Immunization during pregnancy has been recommended in an increasing number of countries. The aim of this strategy is to protect pregnant women and infants from severe infectious disease, morbidity and mortality and is currently limited to tetanus, inactivated influenza, and pertussis-containing vaccines. There have been recent advancements in the development of vaccines designed primarily for use in pregnant women (respiratory syncytial virus and group B Streptococcus vaccines). Although there is increasing evidence to support vaccination in pregnancy, important gaps in knowledge still exist and need to be addressed by future studies. This collaborative consensus paper provides a review of the current literature on immunization during pregnancy and highlights the gaps in knowledge and a consensus of priorities for future research initiatives, in order to optimize protection for both the mother and the infant. © Copyright © 2020 Abu-Raya, Maertens, Edwards, Omer, Englund, Flanagan, Snape, Amirthalingam, Leuridan, Damme, Papaevangelou, Launay, Dagan, Campins, Cavaliere, Frusca, Guidi, O'Ryan, Heininger, Tan, Alsuwaidi, Safadi, Vilca, Wanlapakorn, Madhi, Giles, Prymula, Ladhani, Martinón-Torres, Tan, Michelin, Scambia, Principi and Esposito.
- Published
- 2020
9. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns
- Author
-
Leuridan, E. and Van Damme, P.
- Published
- 2007
- Full Text
- View/download PDF
10. Compliance and immunogenicity of two hepatitis B vaccination schedules in sex workers in Belgium
- Author
-
Wouters, K., Leuridan, E., Van Herck, K., Van Ardenne, N., Roelofs, I., Mak, R., Prévost, C., Guérin, P., Denis, B., and Van Damme, P.
- Published
- 2007
- Full Text
- View/download PDF
11. Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance
- Author
-
Van Herck, K, Leuridan, E, and Van Damme, P
- Published
- 2007
12. Male sex workers in Antwerp, Belgium: a descriptive study
- Author
-
Leuridan, E, Wouters, K, Stalpaert, M, and Van Damme, P
- Published
- 2005
13. Surveillance and prevention of viral hepatitis A and B in Europe: lessons learnt and considerations for the future: Workshop: Surveillance, epidemiology and prevention of hepatitis A and B in Europe: results of the feasibility study: EUROHEP.NET
- Author
-
Van Damme, P, Vorsters, A, Van Herck, K, Leuridan, E, Kojouharova, M, Dagan, R, Bonanni, P, Usonis, V, Magdzik, W, and Hallauer, J
- Published
- 2004
14. Audit on offering and accepting hepatitis B vaccine by sex workers
- Author
-
van Ardenne, N, Roelofs, I, Leuridan, E, Wouters, K, and Van Damme, P
- Published
- 2004
15. Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox (vol 7, 1077, 2017)
- Author
-
Ogunjimi, B, Van den Bergh, J, Meysman, P, Heynderickx, S, Bergs, K, Jansens, H, Leuridan, E, Vorsters, A, Goossens, H, Laukens, K, Cools, N, Van Tendeloo, Viggo, Hens, N, Van Damme, P, Smits, Evelien, Beutels, Ph, and Pediatrics
- Subjects
general ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING - Abstract
The original version of this Article contained an error in the spelling of H. Jansens, which was incorrectly given as H. Jansen in the Article, and as H. Janssen in the Supplementary Information file. This has now been corrected in the HTML and PDF versions of this Article, and in the Supplementary Information file.
- Published
- 2018
16. Author Correction: Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox
- Author
-
Ogunjimi, B., primary, Van den Bergh, J., additional, Meysman, P., additional, Heynderickx, S., additional, Bergs, K., additional, Jansens, H., additional, Leuridan, E., additional, Vorsters, A., additional, Goossens, H., additional, Laukens, K., additional, Cools, N., additional, Van Tendeloo, Viggo, additional, Hens, N., additional, Van Damme, P., additional, Smits, Evelien, additional, and Beutels, Ph., additional
- Published
- 2018
- Full Text
- View/download PDF
17. High susceptibility to cytomegalovirus infection of pregnant women in Flanders, Belgium
- Author
-
Leuridan E, Ieven M, Niel Hens, and Van Damme P
- Subjects
Original Paper ,maternal antibodies ,seroprevalence ,virus diseases ,cord blood ,cytomegalovirus ,pregnancy ,transplacental transport ,Cord blood ,Human medicine - Abstract
Maternal antibodies against cytomegalovirus (CMV) infection offer, to some extent, protection against congenital CMV infection. This study describes the seroprevalence of CMV-specific IgG in 220 parturient women during pregnancy, at delivery, at 3 months after delivery and in their cord blood (Flanders, Belgium, 2006-2008). ELISA was used to measure IgG. Of this population, 30% had positive IgG titres. Active transplacental transport was confirmed with a ratio 1.15/1. Elevated maternal IgG titre and increased parity, but not age, were significantly associated with higher seropreva- lence of CMV-specific IgG in the cord blood. These data indicate a high susceptibility to CMV among fertile women. Prenatal prevention and other strategies to prevent intra-uterine infection are of critical importance in a highly susceptible population.
- Published
- 2012
18. Assessing the risk of measles resurgence in a highly vaccinated population: Belgium anno 2013
- Author
-
Hens, N, primary, Abrams, S, additional, Santermans, E, additional, Theeten, H, additional, Goeyvaerts, N, additional, Lernout, T, additional, Leuridan, E, additional, Van Kerckhove, K, additional, Goossens, H, additional, Van Damme, P, additional, and Beutels, P, additional
- Published
- 2015
- Full Text
- View/download PDF
19. Acquisition of adult-like TLR4 and TLR9 responses during the first year of life
- Author
-
Nguyen, Muriel, Leuridan, E., Zhang, Tong, De Wit, Dominique, Willems, Fabienne, Van Damme, Pierre, Goldman, Michel, Goriely, Stanislas, Nguyen, Muriel, Leuridan, E., Zhang, Tong, De Wit, Dominique, Willems, Fabienne, Van Damme, Pierre, Goldman, Michel, and Goriely, Stanislas
- Abstract
info:eu-repo/semantics/published
- Published
- 2010
20. Should Europe have a universal hepatitis B vaccination programme?
- Author
-
Damme, P. V., primary, Leuridan, E., additional, Hendrickx, G., additional, Vorsters, A., additional, Theeten, H., additional, Leino, T., additional, Salminen, M., additional, and Kuusi, M., additional
- Published
- 2013
- Full Text
- View/download PDF
21. Measles outbreak in Europe: Susceptibility of infants too young to be immunized
- Author
-
Leuridan, E., primary, Sabbe, M., additional, and Van Damme, P., additional
- Published
- 2012
- Full Text
- View/download PDF
22. Hepatitis B and the Need for a Booster Dose
- Author
-
Leuridan, E., primary and Van Damme, P., additional
- Published
- 2011
- Full Text
- View/download PDF
23. Kinetics of maternal antibodies against rubella and varicella in infants
- Author
-
Leuridan, E., primary, Hens, N., additional, Hutse, V., additional, Aerts, M., additional, and Van Damme, P., additional
- Published
- 2011
- Full Text
- View/download PDF
24. P.346 Compliance and immunogenicity of two hepatitis B vaccination schedules in sex workers
- Author
-
Wouters, K., primary, Leuridan, E., additional, Van Ardenne, N., additional, Roelofs, I., additional, Mak, R., additional, Prévost, C., additional, Guérin, P., additional, Denis, B., additional, Van Herck, K., additional, and Van Damme, P.A., additional
- Published
- 2006
- Full Text
- View/download PDF
25. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study
- Author
-
Leuridan, E., Hens, N., Hutse, V., Ieven, M., Aerts, M., and Van Damme, P.
- Subjects
Measles -- Drug therapy ,Measles -- Prevention ,Infants -- Health aspects ,Natural immunity -- Health aspects ,Natural immunity -- Analysis - Published
- 2010
26. Surveillance, epidemiology and prevention of hepatitis A and B in Europe: results of the feasibility study: EUROHEP.NET
- Author
-
Damme, P., Vorsters, A., Koen Van Herck, Leuridan, E., Kojouharova, M., Dagan, R., Bonanni, P., Usonis, V., Magdzik, W., and Hallauer, J.
27. Hepatitis A and B surveillance and immunization programmes in Europe: EUROHEP.NET project
- Author
-
Leuridan, E., Alex Vorsters, Herck, K., Damme, P., Kojouharova, M., Hallauer, J., Dagan, R., Bonanni, P., Boccalini, S., Bechini, A., Usonis, V., and Magdzik, W.
28. Can health programmes lead to mistreatment of sex workers?
- Author
-
Rojanapithayakorn W, Van Damme P, Leuridan E, Wouters K, Mak R, Prévost C, Van Damme, Pierre, Leuridan, Elke, Wouters, Kristien, Mak, Ruud, and Prévost, Colette
- Published
- 2003
- Full Text
- View/download PDF
29. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study
- Author
-
V. Hutse, Maarten Aerts, Elke Leuridan, Niel Hens, Margareta Ieven, P. Van Damme, Leuridan, E., HENS, Niel, Hutse, V., Leven, M., AERTS, Marc, and Van Damme, P.
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Measles Vaccine ,Enzyme-Linked Immunosorbent Assay ,Antibodies, Viral ,Measles ,Young Adult ,Belgium ,Immunity ,Pregnancy ,medicine ,Humans ,Prospective Studies ,Pregnancy Complications, Infectious ,Prospective cohort study ,General Environmental Science ,biology ,business.industry ,General Engineering ,Infant, Newborn ,General Medicine ,medicine.disease ,Vaccination ,Immunization ,Immunoglobulin G ,Immunology ,biology.protein ,General Earth and Planetary Sciences ,Female ,Measles vaccine ,Human medicine ,Antibody ,business ,Immunity, Maternally-Acquired - Abstract
Objective To investigate the duration of the presence of maternal antibodies to measles in infants. Design Prospective study (May 2006 to November 2008). Setting Five hospitals in the Province of Antwerp, Belgium. Participants Of 221 pregnant women recruited, 207 healthy woman-infant pairs were included-divided into a vaccinated group (n=87) and naturally immune group (n=120), according to vaccination documents and history. Main outcome measure Measles IgG antibodies measured by enzyme linked immunosorbent assay (ELISA) at seven time points (week 36 of pregnancy, birth (cord), and 1, 6, 9, and 12 months); decay of maternal antibody in infants modelled with linear mixed models. Results Vaccinated women had significantly fewer IgG antibodies (geometric mean titre 779 (95% confidence interval 581 to 1045) mIU/ml) than did naturally immune women (2687 (2126 to 3373) mIU/ml) (P
- Published
- 2010
30. Unraveling the Immune Signature of Herpes Zoster: Insights Into the Pathophysiology and Human Leukocyte Antigen Risk Profile.
- Author
-
Vandoren R, Boeren M, Schippers J, Bartholomeus E, Mullan K, Michels N, Aerts O, Leysen J, Bervoets A, Lambert J, Leuridan E, Wens J, Peeters K, Emonds MP, Jansens H, Casanova JL, Bastard P, Suls A, Van Tendeloo V, Ponsaerts P, Delputte P, Ogunjimi B, Laukens K, and Meysman P
- Subjects
- Humans, Aged, Male, Middle Aged, Genetic Predisposition to Disease, Female, Adaptive Immunity, United Kingdom epidemiology, Adult, Immunity, Innate, Herpes Zoster immunology, Herpes Zoster virology, Genome-Wide Association Study, Herpesvirus 3, Human immunology, HLA Antigens genetics, HLA Antigens immunology
- Abstract
The varicella-zoster virus (VZV) infects >95% of the population. VZV reactivation causes herpes zoster (HZ), known as shingles, primarily affecting the elderly and individuals who are immunocompromised. However, HZ can occur in otherwise healthy individuals. We analyzed the immune signature and risk profile in patients with HZ using a genome-wide association study across different UK Biobank HZ cohorts. Additionally, we conducted one of the largest HZ human leukocyte antigen association studies to date, coupled with transcriptomic analysis of pathways underlying HZ susceptibility. Our findings highlight the significance of the major histocompatibility complex locus for HZ development, identifying 5 protective and 4 risk human leukocyte antigen alleles. This demonstrates that HZ susceptibility is largely governed by variations in the major histocompatibility complex. Furthermore, functional analyses revealed the upregulation of type I interferon and adaptive immune responses. These findings provide fresh molecular insights into the pathophysiology and activation of innate and adaptive immune responses triggered by symptomatic VZV reactivation., Competing Interests: Potential conflicts of interest. J.-L. C. is an inventor on patent application PCT/US2021/042741 (filed 22 July 2021; submitted by The Rockefeller University), which covers diagnosis of susceptibility to, and treatment of, viral disease and viral vaccines, including COVID-19 and vaccine-associated diseases. B. O., K. L., and P. M. are employees and/or stockholders of Immunewatch, which is a spin-off company focusing on the development of artificial intelligence–based models that give insights into the T-cell response. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
31. Lack of functional TCR-epitope interaction is associated with herpes zoster through reduced downstream T cell activation.
- Author
-
Boeren M, de Vrij N, Ha MK, Valkiers S, Souquette A, Gielis S, Kuznetsova M, Schippers J, Bartholomeus E, Van den Bergh J, Michels N, Aerts O, Leysen J, Bervoets A, Lambert J, Leuridan E, Wens J, Peeters K, Emonds MP, Elias G, Vandamme N, Jansens H, Adriaensen W, Suls A, Vanhee S, Hens N, Smits E, Van Damme P, Thomas PG, Beutels P, Ponsaerts P, Van Tendeloo V, Delputte P, Laukens K, Meysman P, and Ogunjimi B
- Subjects
- Humans, Female, Middle Aged, Male, CD4-Positive T-Lymphocytes immunology, Aged, Adult, Epitopes, T-Lymphocyte immunology, Herpes Zoster immunology, Herpes Zoster virology, Receptors, Antigen, T-Cell metabolism, Receptors, Antigen, T-Cell immunology, Lymphocyte Activation immunology, Herpesvirus 3, Human immunology
- Abstract
The role of T cell receptor (TCR) diversity in infectious disease susceptibility is not well understood. We use a systems immunology approach on three cohorts of herpes zoster (HZ) patients and controls to investigate whether TCR diversity against varicella-zoster virus (VZV) influences the risk of HZ. We show that CD4
+ T cell TCR diversity against VZV glycoprotein E (gE) and immediate early 63 protein (IE63) after 1-week culture is more restricted in HZ patients. Single-cell RNA and TCR sequencing of VZV-specific T cells shows that T cell activation pathways are significantly decreased after stimulation with VZV peptides in convalescent HZ patients. TCR clustering indicates that TCRs from HZ patients co-cluster more often together than TCRs from controls. Collectively, our results suggest that not only lower VZV-specific TCR diversity but also reduced functional TCR affinity for VZV-specific proteins in HZ patients leads to lower T cell activation and consequently affects the susceptibility for viral reactivation., Competing Interests: Declaration of interests K.L., P.M., and B.O. are co-founders, board directors, and shareholders of ImmuneWatch. None of the work presented here was influenced in any way by this. ImmuneWatch had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
32. Immunogenicity at delivery after Tdap vaccination in successive pregnancies.
- Author
-
De Weerdt L, Thiriard A, Leuridan E, Marchant A, and Maertens K
- Subjects
- Pregnancy, Humans, Female, Follow-Up Studies, Antibodies, Bacterial, Immunoglobulin G, Vaccination, Diphtheria-Tetanus-acellular Pertussis Vaccines, Whooping Cough prevention & control, Diphtheria prevention & control, Tetanus prevention & control
- Abstract
Background: Tetanus, diphtheria, acellular pertussis (Tdap) vaccination is recommended to be administered in every pregnancy. Although the safety of this strategy has been confirmed, the immunogenicity of Tdap vaccination in two successive pregnancies has not yet been described. This study investigated Tdap-specific immunity levels and transplacental transfer in two successive pregnancies after repeated Tdap-vaccination., Methods: Women enrolled in prior studies on Tdap vaccination during pregnancy were invited to participate in a follow-up study if they became pregnant again. Women who received a Tdap vaccine in both pregnancies were considered for this analysis. Tdap-specific total IgG and IgG subclasses were measured with a multiplex immunoassay., Results: In total, 27 participants with a mean interval between deliveries of 2.4 years were included in the analysis. In maternal serum, Tdap-specific total IgG levels were comparable at both deliveries whereas in cord serum, all Tdap-specific total IgG antibody levels were reduced at the second compared to the first delivery. This was largely reflected in the IgG1 levels in maternal and cord serum. Transplacental transfer ratios of total IgG and IgG1 were also mostly reduced in the second compared to the first pregnancy., Conclusion: This study reports for the first time Tdap-specific total IgG and IgG subclass levels and transfer ratios after repeated Tdap vaccination in successive pregnancies. We found reduced transfer of most Tdap-specific IgG and IgG1 antibodies in the successive pregnancy. As pertussis-specific antibodies wane quickly, Tdap vaccination in each pregnancy remains beneficial. However, more research is needed to understand the impact of closely spaced booster doses during pregnancy on early infant protection against pertussis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 De Weerdt, Thiriard, Leuridan, Marchant and Maertens.)
- Published
- 2024
- Full Text
- View/download PDF
33. Impact of Maternal Pertussis Antibodies on the Infants' Cellular Immune Responses.
- Author
-
Orije MRP, García-Fogeda I, Van Dyck W, Corbière V, Mascart F, Mahieu L, Hens N, Van Damme P, Cools N, Ogunjimi B, Maertens K, and Leuridan E
- Subjects
- Antibodies, Bacterial, Cytokines, Female, Humans, Immunity, Cellular, Immunization, Secondary, Infant, Infant, Newborn, Infant, Premature, Pertussis Toxin, Pertussis Vaccine, Prospective Studies, Vaccination, Diphtheria-Tetanus-acellular Pertussis Vaccines, Whooping Cough prevention & control
- Abstract
Introduction: Maternal antibody interference of the infant's humoral immune responses raises some concern to the strategy of maternal Tdap (tetanus, diphtheria, acellular pertussis [aP]) vaccination. This study assessed the impact of maternal Tdap antibodies on the infant's pertussis-specific T lymphocyte responses following infant vaccination with an aP containing vaccine, in a term and preterm born cohort., Methods: Heparin samples (±0.5 mL) were conveniently drawn from infants of a Belgian prospective cohort study (N = 79, NCT02511327), including Tdap vaccinated (Boostrix®) and nonvaccinated women (no Tdap vaccine in the last 5 years) that delivered at term or prematurely. Sampling was performed before and 1 month after primary (8-12-16 weeks) and booster vaccination (13 or 15 months) with DTaP-IPV-HB-PRP~T vaccine (Hexyon®). Pertussis toxin (PT)-specific CD3+, CD3+ CD4+ and CD3+ CD8+ lymphoblasts and their cytokine secretions were measured using a flow cytometric assay on whole blood (FASCIA) and multiplex technology (Meso Scale Discovery), respectively., Results: In total, 57% of all infants were considered PT-specific CD3+ CD4+ lymphoblasts responders after primary and booster vaccination, whereas 17% were CD3+ CD8+ lymphoblast responders. Interferon (IFN)-γ, interleukin (IL)-13, IL-17A, and IL-5 cytokine secretions after primary and booster vaccination were indicative of a mixed T helper (Th) 1/Th2/Th17 cell profile. Lymphoblast and cytokine levels were comparable between term and preterm infants. Nonresponders for IL-13 after booster vaccination had higher maternal PT immunoglobulin G (IgG) levels at birth when compared to responders., Conclusions: Term and preterm born infants are capable of inducing Th1, Th2, and Th17 responses after aP vaccination, yet maternal vaccination modulate these responses. Evaluation of this effect in larger trials is needed., Competing Interests: Potential conflicts of interest. The Universities of Antwerp and Hasselt obtain grants from several vaccine manufacturers (GSK Biologicals, Pfizer, Merck, and J&J) for specific studies aimed at modeling the spread of infectious diseases for which N. H. is the principal investigator (PI). N. H. obtains no personal renumeration. The University of Antwerp obtains grants from several small and medium-sized enterprises and vaccine manufacturers (GSK Biologicals, Pfizer, SANOFI, Merck, Takeda, Baxter, CanSino China, Themis, Osivax, J&J, and Abbott) for the conduct of vaccine trials for which P. V. D. is the investigator and for the support of the Viral Hepatitis Prevention Board. P. V. D. obtains no personal remuneration. The University of Antwerp obtains grants from foundations, EU, and Government (The Bill & Melinda Gates Foundation, PATH, Flemish Government, and European Union) for the conduct of trials and vaccine research for which P. V. D. is the PI. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
34. Impact of vaccination during pregnancy on infants' immune responses to vaccinations- definitions and statistical approaches.
- Author
-
Maertens K, Leuridan E, Munoz FM, Zimmermann P, Curtis N, Halperin S, Rots N, Barug D, Holder B, Sadarangani M, and Abu-Raya B
- Subjects
- Female, Humans, Immunization Schedule, Infant, Pregnancy, Immunity, Vaccination
- Abstract
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: MS is supported via salary awards from the BC Children’s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. All other authors declare no competing interest. SH has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, and CanSino; all funds have been paid to his University. SH has also served on ad hoc advisory boards for GSK, Sanofi, Pfizer, AsraZeneca, Merck, and IMV. .
- Published
- 2022
- Full Text
- View/download PDF
35. The Impact of Timing of Pertussis Vaccination During Pregnancy on Infant Antibody Levels at Birth: A Multi-Country Analysis.
- Author
-
Gomme J, Wanlapakorn N, Ha HTT, Leuridan E, Herzog SA, and Maertens K
- Subjects
- Female, Fetal Blood, Humans, Infant, Infant, Newborn, Parturition, Pregnancy, Pregnancy Trimester, Third, Vaccination methods, Whooping Cough prevention & control
- Abstract
Background: Pertussis vaccination during pregnancy is an effective strategy at reducing pertussis-related morbidity and mortality in infancy and is recommended across several countries. However, the optimal timepoint for vaccination in pregnancy to afford maximal protection to newborns is yet to be elucidated. This multi-country analysis aimed to model the impact of timing of vaccination during pregnancy on infant antibody titers at birth., Methods: A multi-country analysis on a cohort of mother-infant pairs (n=698) vaccinated between 19.6-37.1 weeks gestation was conducted. Data taken from four parent studies on pertussis vaccination during pregnancy were modelled using natural cubic splines and linear mixed models to study the association of both gestational age at vaccination and the interval between vaccination and delivery with pertussis-specific cord blood antibody levels after pertussis vaccination during pregnancy., Results: Term born infants on average achieve the highest antibody levels at birth if women are vaccinated before 31 weeks' gestation. When considering both term and preterm deliveries, an interval of at least 7.5 weeks between vaccination and delivery is required to achieve the highest cord blood antibody levels. The models show that vaccinating earlier than these timeframes will also provide the infant with equally high antibody levels at birth., Conclusions: Vaccinating in the second and early third trimester results in the highest antibody levels at birth. Vaccinating earlier within this window is needed to provide equal benefits to both term and preterm born infants., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Gomme, Wanlapakorn, Ha, Leuridan, Herzog and Maertens.)
- Published
- 2022
- Full Text
- View/download PDF
36. Pertussis Immunization During Pregnancy: Assessment of the Role of Maternal Antibodies on Immune Responses in Term and Preterm-Born Infants.
- Author
-
Maertens K, Orije MRP, Herzog SA, Mahieu LM, Hens N, Van Damme P, and Leuridan E
- Subjects
- Antibodies, Bacterial, Female, Humans, Immunity, Immunization, Secondary, Infant, Infant, Newborn, Infant, Premature, Pregnancy, Vaccination, Diphtheria-Tetanus-acellular Pertussis Vaccines, Whooping Cough prevention & control
- Abstract
Background: Limited data exist on the impact of maternal tetanus, diphtheria, acellular pertussis (Tdap) vaccination for preterm born infants. We report its effect at birth and on antibody-mediated immune responses to a DTaP-IPV-HB-PRP~T vaccine in preterm compared with term infants., Methods: Women delivering at term or prematurely were either vaccinated with a Tdap vaccine (Boostrix; GSK) during pregnancy or not vaccinated in the last 5 years. Cord and maternal blood were collected at delivery. Infants were vaccinated with DTaP-IPV-HB-PRP~T vaccine (Hexyon; Sanofi Pasteur) and blood collected before and 1 month after primary (8-12-16 weeks) and before and 1 month after booster vaccination (13 or 15 months for preterm and term, respectively). Immunoglobulin G antibodies against all antigens included in DTaP-IPV-HB-PRP~T vaccine were measured (NCT02511327)., Results: Cord blood geometric mean concentrations (GMCs) in preterm infants from Tdap-vaccinated women were significantly higher than in term and preterm infants from unvaccinated women. A longer time interval between maternal vaccination and delivery resulted in higher cord blood GMCs in preterm infants. Equal GMCs in term and preterm infants from Tdap-vaccinated women were observed after primary vaccination. After boosting, significantly lower GMCs were seen for pertussis toxin, filamentous hemagglutinin, and tetanus toxoid in preterm compared with term infants from Tdap-vaccinated women, yet still comparable to GMCs in both term and preterm infants from unvaccinated women., Conclusions: Preterm infants profit from maternal Tdap vaccination. Prematurity did not influence primary immune responses in the presence of maternal antibodies but was associated with a lower booster immune response., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
37. The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis.
- Author
-
Oguti B, Ali A, Andrews N, Barug D, Anh Dang D, Halperin SA, Thu Hoang HT, Holder B, Kampmann B, Kazi AM, Langley JM, Leuridan E, Madavan N, Maertens K, Maldonado H, Miller E, Munoz-Rivas FM, Omer SB, Pollard AJ, Rice TF, Rots N, Sundaram ME, Wanlapakorn N, and Voysey M
- Subjects
- Antibodies, Bacterial, Diphtheria-Tetanus-Pertussis Vaccine, Female, Half-Life, Humans, Infant, Infant, Newborn, Pregnancy, Tetanus Toxoid, Diphtheria prevention & control, Tetanus prevention & control, Whooping Cough prevention & control
- Abstract
Aim: There are few reliable estimates of the half-lives of maternal antibodies to the antigens found in the primary series vaccines. We aimed to calculate the half-lives of passively acquired diphtheria, tetanus and pertussis (DTP) antibodies in infants. We aimed to determine whether decay rates varied according to country, maternal age, gestational age, birthweight, World Bank income classifications, or vaccine received by the mother during pregnancy., Methods: De-identified data from infants born to women taking part in 10 studies, in 9 countries (UK, Belgium, Thailand, Vietnam, Canada, Pakistan, USA, Guatemala and the Netherlands) were combined in an individual participant data meta-analysis. Blood samples were taken at two timepoints before any DTP-containing vaccines were received by the infant: at birth and at 2-months of age. Decay rates for each antigen were log
2 -transformed and a mixed effects model was applied. Half-lives were calculated by taking the reciprocal of the absolute value of the mean decay rates., Results: Data from 1426 mother-infant pairs were included in the analysis. The half-lives of the 6 antigen-specific maternal antibodies of interest were similar, with point estimates ranging from 28.7 (95% CI: 24.4 - 35) days for tetanus toxoid antibodies to 35.1 (95% CI: 30.7 - 41.1) days for pertactin antibodies. The decay of maternal antibodies did not significantly differ by maternal age, gestational age, birthweight, maternal vaccination status or type of vaccine administered., Conclusion: Maternal antibodies decay at different rates for the different antigens; however, the magnitude of the difference is small. Decay rates are not modified by key demographic or vaccine characteristics., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [AJP is Chair of UK Dept. Health Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI) and is a member of the WHO’s Strategic Advisory Group of Experts. JML holds the CIHR-GSK Chair in Pediatric Vaccinology at Dalhousie University. JML’s institution has received funding for maternal vaccine studies from Sanofi-Pasteur, GSK and Janssen. The views expressed in this article do not necessarily represent the views of DHSC, JCVI or WHO.]., (Copyright © 2021. Published by Elsevier Ltd.)- Published
- 2022
- Full Text
- View/download PDF
38. Factors affecting antibody responses to immunizations in infants born to women immunized against pertussis in pregnancy and unimmunized women: Individual-Participant Data Meta-analysis.
- Author
-
Abu-Raya B, Maertens K, Munoz FM, Zimmermann P, Curtis N, Halperin SA, Rots N, Barug D, Holder B, Rice TF, Kampmann B, Leuridan E, and Sadarangani M
- Subjects
- Antibodies, Bacterial, Antibody Formation, Diphtheria-Tetanus-Pertussis Vaccine, Female, Humans, Immunization, Secondary, Infant, Pregnancy, Diphtheria-Tetanus-acellular Pertussis Vaccines, Whooping Cough prevention & control
- Abstract
Background: Exploring factors that affect immune responses to immunizations in infants born to women immunized with tetanus-diphtheria-acellular-pertussis (Tdap) in pregnancy compared with unimmunized women is important in designing immunization programs., Methods: Individual-participant data meta-analysis of 8 studies reporting post-immunization immunoglobulin G (IgG) levels to vaccine antigens in infants born to either women immunized with Tdap in pregnancy or unimmunized women, using mixed-effects models., Results: In infants of Tdap-immunized women, two-fold higher levels of anti-pertussis toxin (PT) and anti-diphtheria-toxoid (DT) IgG pre-primary immunization were associated with 9% and 10% lower post-primary immunization levels, (geometric mean ratio [GMR], PT: 0.91; 95% CI, 0.88-0.95,n = 494, DT: 0.9; 0.87-0.93,n = 519). Timing of immunization in pregnancy did not affect post-primary immunization anti-Bordetella pertussis, anti-tetanus-toxoid (TT) and anti-DT IgG levels. Spacing of infant immunization did not affect post-primary immunization anti-B. pertussis and anti-DT levels. In infants of Tdap-immunized women, two-fold higher levels of anti-PT and anti-filamentous haemagglutinin (FHA) IgG pre-primary immunization were associated with lower post-booster immunization levels, (GMR, PT: 0.91; 0.85-0.97,n = 224, FHA: 0.92; 0.85-0.99,n = 232). Timing of immunization in pregnancy did not affect post-booster immunization anti-Bordetella pertussis, anti-tetanus-toxoid (TT) and anti-DT IgG levels. Spacing of infant immunization did not affect post-booster immunization anti-PT, anti-pertactin (PRN), anti-TT and anti-DT IgG levels. In infants of unimmunized women, two-fold higher IgG levels of some vaccine antigens pre-primary immunization were associated with 8-17% lower post-primary immunization levels (GMR, PT 0.92, 95% CI:0.88-0.97, n = 373; FHA:0.88, 95% CI:0.85-0.92,n = 378; PRN:0.84, 95% CI:0.81-0.88, n = 367; TT:0.88, 95% CI:0.83-0.93, n = 241; DT: 0.83, 95% CI:0.79-0.87,n = 278). Two-fold higher levels of anti-FHA IgG pre-primary immunization were associated with 8% lower post-booster immunization levels (GMR, 0.92; 95% CI: 0.86-0.99,n = 138)., Discussion: Increased IgG levels pre-primary immunization is associated with reduced post-primary and post-booster immunization levels for some antigens in infants of women immunized or unimmunized in pregnancy, but their clinical significance is uncertain., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
39. Breast Milk Antibody Levels in Tdap-Vaccinated Women After Preterm Delivery.
- Author
-
Orije MRP, Larivière Y, Herzog SA, Mahieu LM, Van Damme P, Leuridan E, and Maertens K
- Subjects
- Antibodies, Bacterial, Female, Humans, Infant, Newborn, Lactation, Milk, Human, Pregnancy, Diphtheria-Tetanus-acellular Pertussis Vaccines, Premature Birth, Whooping Cough prevention & control
- Abstract
Background: Enrichment of breast milk (BM) with immunoglobulin (Ig) A and IgG through maternal vaccination could help infants combat targeted pathogens. However, evidence on this effect after preterm delivery is lacking. In this study, we investigated the total and anti-pertussis toxin (anti-PT)-specific IgA and IgG production in BM after term and preterm delivery in the presence of maternal Tdap (tetanus, diphtheria, acellular pertussis) vaccination., Methods: Serum and BM samples of lactating women who delivered at term or prematurely and did or did not receive Tdap vaccine (Boostrix, GSK Biologicals) during pregnancy were collected as part of a clinical study (N = 234). Anti-PT IgA/IgG (IBL assay; Meso Scale Discovery assay) and total IgA/IgG (Thermofisher, on BM samples only) immunosorbent assays were performed on all samples collected at 72 hours and 4, 8, and 12 weeks postpartum., Results: BM after preterm delivery contained anti-PT IgA and IgG geometric mean concentrations (GMCs) comparable to those after term delivery (eg, colostrum anti-PT IgA, 5.39 IU/mL vs 6.69 IU/mL, respectively). Maternal Tdap vaccination induced significantly higher anti-PT IgG GMCs in colostrum of vaccinated compared with unvaccinated women who delivered at term (0.110 IU/mL vs 0.027 IU/mL, P = .009). Anti-PT antibodies persisted up to 12 weeks postpartum., Conclusions: This study provides evidence that maternal Tdap vaccination induces high Ig levels in BM after both term and preterm delivery and that these antibodies remain abundantly present throughout lactation, possibly offering additional mucosal protection during the most vulnerable period in early life., Clinical Trial Registration: NCT02511327., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
40. The Effect of Tetanus-Diphtheria-Acellular-Pertussis Immunization During Pregnancy on Infant Antibody Responses: Individual-Participant Data Meta-Analysis.
- Author
-
Abu-Raya B, Maertens K, Munoz FM, Zimmermann P, Curtis N, Halperin SA, Rots N, Barug D, Holder B, Kampmann B, Leuridan E, and Sadarangani M
- Subjects
- Diphtheria prevention & control, Female, Humans, Infant, Pregnancy, Tetanus prevention & control, Vaccination, Whooping Cough prevention & control, Antibodies, Bacterial blood, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, Immunoglobulin G blood
- Abstract
Background: Immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in pregnancy is increasingly recommended. We determined the effect of Tdap immunization in pregnancy on infants' vaccine responses., Methods: Individual-participant data meta-analysis of ten studies (n=1884) investigating infants' antibody response to routine immunizations following Tdap immunization in pregnancy was performed. Geometric mean ratios (GMRs) of antigen-specific immunoglobulin G (IgG) levels were calculated using mixed-effects models. Seroprotection rates were compared using chi-squared tests., Results: Infants of Tdap-immunized women had significantly lower IgG against pertussis toxin (GMR 0.65; 95%CI 0.57-0.74), filamentous haemagglutinin (FHA) (0.68; 0.53-0.87), pertactin (0.65; 0.58-0.72) and fimbria 2/3 (FIM2/3) (0.41; 0.32-0.52) after primary immunization, compared with infants of unimmunized women. These lower levels persisted after booster immunization for FHA (0.72; 0.61-0.84) and FIM2/3 (0.53; 0.29-0.96). After primary immunization, infants of Tdap-immunized women had lower seroprotection rates against diphtheria (90% [843/973] vs 98% [566/579]; p<0.001) and invasive pneumococcal disease (IPD) caused by 5 Streptococcus pneumoniae (SPN) serotypes (SPN5, SPN6B, SPN9V, SPN19A, SPN23F), and higher seroprotection rates against Haemophilus influenzae type b (short-term and long-term seroprotection rates, 86%[471/547] vs 76%[188/247] and 62%[337/547] vs 49%(121/247), respectively, all p=0.001). After booster immunization, seroprotection rates against diphtheria and tetanus were 99% (286/288) and (618/619) in infants of Tdap-immunized women, respectively., Conclusions: Infants of Tdap-immunized women in pregnancy had lower IgG levels against pertussis, diphtheria and some SPN serotypes after their immunization compared with infants of unimmunized women. Enhanced surveillance of pertussis, diphtheria and IPD in infants is needed to determine the clinical significance of these findings., Systematic Review Registration: CRD42017079171., Competing Interests: BA-R is supported by the Canadian Health and Research Institute Vanier Canada Graduate scholarship. KM is the beneficiary of a postdoctoral mandate fellowship from the Fund for Scientific Research-Flanders (FWO 12R5819). MS is supported via salary awards from the BC Children’s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. SH has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, and CanSino; all funds have been paid to his University. SH has also served on ad hoc advisory boards for GSK, Sanofi, Pfizer, AsraZeneca, Merck, and IMV. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Abu-Raya, Maertens, Munoz, Zimmermann, Curtis, Halperin, Rots, Barug, Holder, Kampmann, Leuridan and Sadarangani.)
- Published
- 2021
- Full Text
- View/download PDF
41. The Fifth International Neonatal and Maternal Immunization Symposium (INMIS 2019): Securing Protection for the Next Generation.
- Author
-
Sadarangani M, Kollmann T, Bjornson G, Heath P, Clarke E, Marchant A, Levy O, Leuridan E, Ulloa-Gutierrez R, Cutland CL, Kampmann B, Chaithongwongwatthana S, Dinleyici E, van Damme P, and Munoz FM
- Subjects
- Female, Humans, Infant Health, Infant, Newborn, Maternal Health, Pregnancy, COVID-19 Vaccines immunology, Pregnancy Complications, Infectious prevention & control, Vaccination adverse effects
- Abstract
Despite significant progress in reaching some milestones of the United Nations Sustainable Development Goals, neonatal and early infant morbidity and mortality remain high, and maternal health remains suboptimal in many countries. Novel and improved preventative strategies with the potential to benefit pregnant women and their infants are needed, with maternal and neonatal immunization representing effective approaches. Experts from immunology, vaccinology, infectious diseases, clinicians, industry, public health, and vaccine-related social sciences convened at the 5th International Neonatal and Maternal Immunization Symposium (INMIS) in Vancouver, Canada, from 15 to 17 September 2019. We critically evaluated the lessons learned from recent clinical studies, presented cutting-edge scientific progress in maternal and neonatal immunology and vaccine development, and discussed maternal and neonatal immunization in the broader context of infectious disease epidemiology and public health. Focusing on practical aspects of research and implementation, we also discussed the safety, awareness, and perception of maternal immunization as an existing strategy to address the need to improve maternal and neonatal health worldwide. The symposium provided a comprehensive scientific and practical primer as well as an update for all those with an interest in maternal and neonatal infection, immunity, and vaccination. The summary presented here provides an update of the current status of progress in maternal and neonatal immunization., (Copyright © 2021 Sadarangani et al.)
- Published
- 2021
- Full Text
- View/download PDF
42. Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid).
- Author
-
Abu-Raya B, Migliori GB, O'Ryan M, Edwards K, Torres A, Alffenaar JW, Märtson AG, Centis R, D'Ambrosio L, Flanagan K, Hung I, Lauretani F, Leung CC, Leuridan E, Maertens K, Maggio MG, Nadel S, Hens N, Niesters H, Osterhaus A, Pontali E, Principi N, Rossato Silva D, Omer S, Spanevello A, Sverzellati N, Tan T, Torres-Torreti JP, Visca D, and Esposito S
- Abstract
Coronavirus disease 2019 (COVID-19) is a rapidly evolving, highly transmissible, and potentially lethal pandemic caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of June 11 2020, more than 7,000,000 COVID-19 cases have been reported worldwide, and more than 400,000 patients have died, affecting at least 188 countries. While literature on the disease is rapidly accumulating, an integrated, multinational perspective on clinical manifestations, immunological effects, diagnosis, prevention, and treatment of COVID-19 can be of global benefit. We aimed to synthesize the most relevant literature and experiences in different parts of the world through our global consortium of experts to provide a consensus-based document at this early stage of the pandemic., (Copyright © 2020 Abu-Raya, Migliori, O'Ryan, Edwards, Torres, Alffenaar, Märtson, Centis, D'Ambrosio, Flanagan, Hung, Lauretani, Leung, Leuridan, Maertens, Maggio, Nadel, Hens, Niesters, Osterhaus, Pontali, Principi, Rossato Silva, Omer, Spanevello, Sverzellati, Tan, Torres-Torreti, Visca and Esposito.)
- Published
- 2020
- Full Text
- View/download PDF
43. Elucidating the difference in the kinetics of antibody titres of infants in Belgium and Vietnam.
- Author
-
Tran TMP, Maertens K, Hoang HTT, Van Damme P, Leuridan E, and Hens N
- Subjects
- Antibodies, Bacterial, Belgium, Child, Female, Humans, Immunization, Secondary, Infant, Kinetics, Pregnancy, Vaccination, Vietnam, Diphtheria-Tetanus-acellular Pertussis Vaccines, Whooping Cough
- Abstract
Serological results obtained in a single laboratory from twin-studies on maternal immunisation, in Vietnam and Belgium offer the opportunity to compare antibody kinetics in infants before and after infant vaccination in the presence of vaccine-induced maternal antibodies. Nonlinear mixed-effects models (NLMMs) making use of a hypothesised dynamic evolution that captures the change in antibody titres over time, were employed to model anti-PT and anti-Prn antibody dynamics. Our proposed modelling approach provided useful insight into understanding the differences in the infants' antibody kinetics in both countries since NLMMs offer the possibility of pooling all data in one analysis and incorporate relevant covariates of interest. In both controlled cohort studies, pregnant women were vaccinated with a tetanus, diphtheria, acellular pertussis (Tdap) vaccine (Boostrix®, Belgium; Adacel®, Vietnam), and children were followed before and after primary vaccination, and before and after booster vaccination (Infanrix hexa®). From our models, both anti-PRN and anti-PT antibody titres at birth of Vietnamese infants were significantly lower than those of Belgian infants born to vaccinated women groups. Even though the antibody titres in the cord at birth of Belgian infants were also higher than those of Vietnamese infants born to the control women groups, the difference was not significant. The significant difference between infants born to vaccinated women in the two countries was likely due to the use of different vaccine brands in pregnant women and the different vaccination histories of women in these two countries. Our analyses also suggested that the blunting effect was present during the primary immunisation but went away afterward for anti-PT data. In contrast, for anti-PRN antibodies, the blunting effect persisted after the primary vaccination and possibly went away after the booster dose. Countries should be aware of the regional situation in view of recommending maternal immunization., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Declaration of Competing Interest statement The authors do not have commercial or other association that might pose a conflict of interest (e.g., pharmaceutical stock ownership, consultancy, pharmaceutical board membership, relevant patents, or research funding)., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
44. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers.
- Author
-
Wanlapakorn N, Maertens K, Thongmee T, Srimuan D, Thatsanathorn T, Van Damme P, Leuridan E, and Poovorawan Y
- Subjects
- Antibodies, Bacterial, Child, Diphtheria-Tetanus-Pertussis Vaccine, Female, Humans, Immunization, Secondary, Infant, Infant, Newborn, Mothers, Pregnancy, Thailand, Diphtheria prevention & control, Diphtheria-Tetanus-acellular Pertussis Vaccines, Haemophilus Vaccines, Haemophilus influenzae type b, Tetanus, Whooping Cough prevention & control
- Abstract
Introduction: Vaccination of pregnant women protects both women and their newborns against some infectious diseases. Thailand implemented tetanus toxoid (TT) vaccination of pregnant women in 1977, which was replaced by tetanus-diphtheria toxoid (dT) vaccination in 2005. The tetanus-diphtheria-acellular pertussis (Tdap) vaccine has been recommended for pregnant women at 27-36 weeks of gestation since 2012 in several countries. Data on antibody responses to diphtheria toxoid (DT), TT, and Hemophilus influenzae type b (Hib) induced by combined vaccines in children born to TT-vaccinated and/or Tdap-vaccinated mothers are limited., Material and Methods: We investigated anti-DT, anti-TT, and anti-Hib IgG responses in a cohort of Thai children (ClinicalTrial.gov NCT02408926) born to mothers who received a TT-containing and/or the Tdap vaccine during pregnancy. Children born to Tdap-vaccinated mothers were randomized to receive either a hexavalent (Infanrix-hexa) or pentavalent (Quinvaxem) vaccine, whereas children born to TT-vaccinated mothers received only Quinvaxem vaccine at 2, 4, 6, and 18 months of age. IgG levels were evaluated at birth (cord blood), 2 (pre-primary), 7 (post-primary), 18 (pre-booster), and 19 months of age (post-booster) using a commercially available enzyme-linked immunoassay., Results: Seroprotective concentrations of anti-DT, anti-TT, and anti-Hib IgG were achieved in >90% and >99% of children following primary and booster vaccination, respectively. Among children born to Tdap-vaccinated mothers, the pentavalent vaccine induced higher levels of anti-Hib IgG than the hexavalent vaccine after primary and booster vaccination. Significantly higher anti-Hib IgG levels were observed among children receiving the pentavalent vaccine and who were born to TT-vaccinated mothers than among children receiving the pentavalent vaccine and born to Tdap-vaccinated mothers after primary and booster vaccination., Conclusions: Vaccination with a TT-containing and/or the Tdap vaccine during pregnancy did not compromise the seroprotection rate achieved following primary and booster immunization in individuals receiving either the pentavalent or hexavalent vaccine., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
45. Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial.
- Author
-
Wanlapakorn N, Maertens K, Vongpunsawad S, Puenpa J, Tran TMP, Hens N, Van Damme P, Thiriard A, Raze D, Locht C, Poovorawan Y, and Leuridan E
- Subjects
- Antibodies, Bacterial, Child, Female, Humans, Immunization, Secondary, Infant, Mothers, Pertussis Vaccine, Pregnancy, Thailand, Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines, Tetanus prevention & control, Whooping Cough prevention & control
- Abstract
Background: The blunting effect of pertussis immunization during pregnancy on infant antibody responses induced by whole-cell pertussis (wP) vaccination is not well-defined., Methods: This randomized controlled trial (NCT02408926) followed term infants born to mothers vaccinated with tetanus, diphtheria, and acellular pertussis (Tdap) vaccine during pregnancy in Thailand. Infants received either acellular pertussis (aP)- or wP-containing vaccine at 2, 4, 6, and 18 months of age. A comparison group comprised wP-vaccinated children born to mothers not vaccinated during pregnancy. Antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN) were evaluated using commercial enzyme-linked immunosorbent assays. Functionality of antibodies against Bordetella pertussis was measured using Bordetella pertussis growth inhibition assay., Results: After maternal Tdap vaccination, 158 infants vaccinated with aP-containing vaccines possessed higher antibody levels (P < .001) against all tested B. pertussis antigens postpriming compared to 157 infants receiving wP-containing vaccines. At 1 month postbooster, only anti-FHA and anti-PRN antibodies were still significantly higher (P < .001) in the aP group. Significantly higher anti-PT and anti-FHA (P < .001), but not anti-PRN immunoglobulin G, were observed among 69 wP-vaccinated infants born to control mothers compared with wP-vaccinated infants of Tdap-vaccinated mothers after primary and booster vaccination. The antibody functionality was higher in all wP-vaccinated infants at all times., Conclusions: Maternal Tdap vaccination inhibited more pertussis-specific responses in wP-vaccinated infants compared to aP-vaccinated infants, and the control group of unvaccinated women had highest PT-specific responses, persisting until after the booster dose. Antibody functionality was better in the wP groups., Clinical Trials Registration: NCT02408926.Infant whole-cell pertussis (wP) vaccine responses are blunted after maternal Tdap vaccination. Pertussis antibody titers are higher in acellular pertussis (aP)- than wP-vaccinated infants of immunized mothers, yet quality of antibodies, measured as serum-mediated bacterial growth inhibition, is better after wP than aP vaccination., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
46. Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement.
- Author
-
Abu-Raya B, Maertens K, Edwards KM, Omer SB, Englund JA, Flanagan KL, Snape MD, Amirthalingam G, Leuridan E, Damme PV, Papaevangelou V, Launay O, Dagan R, Campins M, Cavaliere AF, Frusca T, Guidi S, O'Ryan M, Heininger U, Tan T, Alsuwaidi AR, Safadi MA, Vilca LM, Wanlapakorn N, Madhi SA, Giles ML, Prymula R, Ladhani S, Martinón-Torres F, Tan L, Michelin L, Scambia G, Principi N, and Esposito S
- Subjects
- Clinical Trials as Topic ethics, Consensus, Ethics, Medical, Female, Global Health, Health Impact Assessment, Health Priorities, Humans, Immunogenicity, Vaccine, Maternal Exposure, Pregnancy, Prenatal Exposure Delayed Effects, Research, Risk Assessment, Risk Factors, Vaccination, Vaccines administration & dosage, Vaccines adverse effects, Vaccines immunology, Immunization adverse effects, Immunization ethics, Immunization methods, Immunization trends, Pregnancy Complications, Infectious epidemiology, Pregnancy Complications, Infectious prevention & control
- Abstract
Immunization during pregnancy has been recommended in an increasing number of countries. The aim of this strategy is to protect pregnant women and infants from severe infectious disease, morbidity and mortality and is currently limited to tetanus, inactivated influenza, and pertussis-containing vaccines. There have been recent advancements in the development of vaccines designed primarily for use in pregnant women (respiratory syncytial virus and group B Streptococcus vaccines). Although there is increasing evidence to support vaccination in pregnancy, important gaps in knowledge still exist and need to be addressed by future studies. This collaborative consensus paper provides a review of the current literature on immunization during pregnancy and highlights the gaps in knowledge and a consensus of priorities for future research initiatives, in order to optimize protection for both the mother and the infant., (Copyright © 2020 Abu-Raya, Maertens, Edwards, Omer, Englund, Flanagan, Snape, Amirthalingam, Leuridan, Damme, Papaevangelou, Launay, Dagan, Campins, Cavaliere, Frusca, Guidi, O'Ryan, Heininger, Tan, Alsuwaidi, Safadi, Vilca, Wanlapakorn, Madhi, Giles, Prymula, Ladhani, Martinón-Torres, Tan, Michelin, Scambia, Principi and Esposito.)
- Published
- 2020
- Full Text
- View/download PDF
47. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth.
- Author
-
Posuwan N, Wanlapakorn N, Vongpunsawad S, Sintusek P, Leuridan E, Van Damme P, and Poovorawan Y
- Subjects
- Hepatitis B prevention & control, Hepatitis B Surface Antigens immunology, Humans, Immunization Schedule, Immunization, Secondary, Infant, Infant, Newborn, Thailand, Vaccination, Vaccines, Combined administration & dosage, Diphtheria-Tetanus-Pertussis Vaccine administration & dosage, Haemophilus Vaccines administration & dosage, Hepatitis B Antibodies blood, Hepatitis B Vaccines administration & dosage, Poliovirus Vaccine, Inactivated administration & dosage
- Abstract
Background: In Thailand, the hepatitis B (HB) vaccine is administered as a tetravalent vaccine (DTwP-HB) to all infants at 2, 4, and 6 months of age, following an initial vaccination with a monovalent HB vaccine at birth. As part of ongoing vaccine evaluation, we aimed to compare the hepatitis B immunogenicity profiles of children who had received either the pentavalent (DTwP-HB-Hib) or the hexavalent (DTaP-HB-Hib-IPV) vaccine., Methods: Two groups of infants, whose mothers previously received the tetanus-diphtheria-acellular pertussis vaccine (Tdap), were randomly vaccinated with either pentavalent or hexavalent vaccine at 2, 4, 6, and 18 months of age, following monovalent HB vaccine at birth. Blood samples were obtained at birth, one-month post-primary series immunization (mo 7), pre-booster (mo 18), one-month post-booster (mo 19), and six months post-booster (mo 24). The third group of infants, whose mothers did not receive Tdap, was vaccinated with DTwP-HB-Hib (EPI pentavalent group). Levels of HBsAg, anti-HBc, and anti-HBs were evaluated by means of an automated Chemiluminescent Microparticle Immunoassay., Results: Anti-HBs levels of ≥10 mIU/ml were achieved in 99.2% (hexavalent group), 99.2% (pentavalent group), and 98.5% (EPI pentavalent group) of infants, after four-dose immunization (at 0, 2, 4, 6 months of age). One month after the additional dose given at 18 months of age, anti-HBs levels of ≥10 mIU/ml were observed in 100% (hexavalent group), 99.2% (pentavalent group), and 93.8% (EPI pentavalent group) of infants. At 24 months of age, higher percentages of infants achieving anti-HBs levels ≥10 mIU/ml were found in the hexavalent group (98.3%) compared to the pentavalent group (86.5%)., Conclusions: Both vaccines were effective in inducing anti-HBs levels of ≥10 mIU/ml, and therefore either can be used as a single formula booster at 18 months of age to simplify vaccine administration under the Expanded Program on Immunization in Thailand., Competing Interests: Declaration of Competing Interest P. V. D. reports grants to the University of Antwerp from GSK Biologicals, Merck, SP, MSD, Pfizer, Sanofi, Takeda, Baxter, CanSino China, Themis, Johnson Johnson, the Bill Melinda Gates Foundation, the Flemish government, the European Union, and Abbott. All other authors report no potential conflicts of interest that could have appeared to influence the work reported in this paper., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
48. Vaccination during pregnancy: current and possible future recommendations.
- Author
-
Maertens K, Orije MRP, Van Damme P, and Leuridan E
- Subjects
- Female, Forecasting, Humans, Immunization methods, Infant, Newborn, Influenza, Human prevention & control, Pregnancy, Risk Assessment, Tetanus prevention & control, Whooping Cough prevention & control, World Health Organization, Infant Health, Maternal Health, Practice Guidelines as Topic, Pregnancy Complications, Infectious prevention & control, Vaccination methods
- Abstract
Immunizing pregnant women to protect the mother, fetus and infant from infection has increasingly been used over the last decade. Protection against infectious diseases in neonates is mainly provided by maternal antibodies transferred from mother to infant during pregnancy through transplacental transport or after delivery via breastfeeding. Both the transplacental- and breast milk-derived maternal antibodies function as the primary source of protection against infectious diseases in neonates during the first vulnerable weeks of life. During recent infectious disease outbreaks (influenza, pertussis, Zika…) and for other infectious diseases (CMV, GBS…), pregnant women are increasingly identified as an important target for vaccination. For some of these diseases, vaccines are already on the market, and recommended during pregnancy. For others, vaccines are currently under development; furthermore, some are even specifically designed to be administered during pregnancy.Conclusion: This review article provides an overview on the rationale and main mechanism of the maternal vaccination strategy and gives a summary about the current and possible future recommendations for maternal vaccination.What is Known:• Maternal vaccination has a far-reaching potential in the protection of both women and offspring.• Currently, tetanus, pertussis and influenza vaccination during pregnancy is recommended in some countries. Several new vaccines specifically designed for use in pregnancy are currently under development.What is New:• Review providing a timely overview of the rationale and main mechanisms of the maternal vaccination strategy• Up-to-date summary of the current and possible future recommendations for maternal vaccination.
- Published
- 2020
- Full Text
- View/download PDF
49. The effect of maternal antibodies on the cellular immune response after infant vaccination: A review.
- Author
-
Orije MRP, Maertens K, Corbière V, Wanlapakorn N, Van Damme P, Leuridan E, and Mascart F
- Subjects
- Animals, Female, Humans, Immunity, Cellular drug effects, Immunity, Humoral drug effects, Immunity, Maternally-Acquired drug effects, Infant, Pregnancy, Vaccination trends, Immunity, Cellular immunology, Immunity, Humoral immunology, Immunity, Maternally-Acquired immunology, Vaccination methods, Vaccines administration & dosage, Vaccines immunology
- Abstract
During the last few decades, maternal immunization as a strategy to protect young infants from infectious diseases has been increasingly recommended, yet some issues have emerged. Studies have shown that for several vaccines, such as live attenuated, toxoid and conjugated vaccines, high maternal antibody titers inhibit the infant's humoral immune response after infant vaccination. However, it is not clear whether this decreased antibody titer has any clinical impact on the infant's protection, as the cellular immune responses are often equally important in providing disease protection and may therefore compensate for diminished antibody levels. Reports describing the effect of maternal antibodies on the cellular immune response after infant vaccination are scarce, probably because such studies are expensive, labor intensive and utilize poorly standardized laboratory techniques. Therefore, this review aims to shed light on what is currently known about the cellular immune responses after infant vaccination in the presence of high (maternal) antibody titers both in animal and human studies. Overall, the findings suggest that maternally derived antibodies do not interfere with the cellular immune responses after infant vaccination. However, more research in humans is clearly needed, as most data originate from animal studies., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
50. Maternal pertussis immunisation as the first infant dose.
- Author
-
Maertens K and Leuridan E
- Subjects
- Family, Humans, Immunization Schedule, Infant, Netherlands, Vaccination, Whooping Cough
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.